|
拉索昔芬市场分析报告
|
cis-Lasofoxifene (CAS 180915-78-0) Market Research Report 2025 BAC Reports offers its clients in-depth market research of chemical industry products on the global and regional markets (North & Latin America, Asia Pacific, European Union, Russia and CIS).
Global Market Report of Lasofoxifene D-glucuronide (CAS 1048953-95-2) December 2024
Global Market Report of Lasofoxifene (CAS 180916-16-9) December 2024
Global Market Report of Lasofoxifene tartrate (CAS 190791-29-8) December 2024
CAS 1048953-95-2 Lasofoxifene D-glucuronide Chemical Report & Database ... Report & Database definitions: Name: Lasofoxifene D-glucuronide: Lasofoxifene-D-glucuronide; (5R,6S)-5,6,7,8-Tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl ... : Chemical or Reaction Intermediate The Lasofoxifene D-glucuronide Report & Database gives Market ...
CAS 190791-29-8 Lasofoxifene tartrate Chemical Report & Database ... Report & Database definitions: Name: Lasofoxifene tartrate: Lasofoxifene-tartrate; (5R,6S)-5,6,7,8-Tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl ... APPLICATIONS: Chemical or Reaction Intermediate The Lasofoxifene tartrate Report & Database gives Market ...
Ligand Pharmaceuticals Inc. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis ... osteoporosis in women at increased risk of fracture. Lasofoxifene Program Lasofoxifene (FABLYN) is a product candidate that ...
Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H2 2017 Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H2 2017 SUMMARY Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H2 2017, provides an overview of the Vaginal ...
Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H1 2018 Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H1 2018 SUMMARY Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H1 2018, provides an overview of the Vaginal ...
Osteoporosis Therapeutics: Market Research Report This report analyzes the worldwide markets for Osteoporosis Therapeutics in US$ Million by the following Therapeutic Classes: Bisphosphonates, ERT Drugs, SERMs, Calcitonins, and MAB (Denosumab). The report provides separate comprehensive analytics for the ...
Osteoporosis Drugs Market – By Drug Class (Bisphosphonates, Parathyroid Hormone Therapy, Selective Estrogen Receptor Modulator, RANK Ligand Inhibitors, Biosimilars, and Others), By Regions (North America, Europe, Asia Pacific, and Rest of the World) – Global Forecast up to 2025 ... . Novo Nordisk A/S Key Competitive Facts: Lasofoxifene (a new selective estrogen receptor modulator ...
Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market - 2025 -2033 ... Phase 3 clinical study comparing targeted lasofoxifene in combination with the CDK 4/6 inhibitor ...
The Pfizer Intelligence Dossier In boardrooms, around water coolers and behind closed office doors, decision-makers in the pharmaceutical industry are asking questions: What’s happening with Pfizer? What developments have occurred in the last quarter? And how will it affect us? With ...
|
|
|